Inhibition der Glukosereabsorption im proximalen Tubulus – Neues Therapieprinzip bei Typ-2-Diabetes

Aufgrund der weiter stark ansteigenden Prävalenz des Typ-2-Diabetes steht in der Arzneimittelentwicklung vor allem die Suche und systematische klinische Erprobung effektiver und sicherer neuer Arzneimittel zur Blutzuckerkontrolle im Vordergrund. Über Erfahrungen mit der Inhibition der Glukosereabsorption im proximalen Nierentubulus (SGLT2-Inhibition) wird im Folgenden berichtet.

Type 2 diabetes continues to increase steeply. This has prompted drug producers to highlight the search for effective and safe new drugs for blood sugar control and for their systematic clinical testing. The present article reports on experiences with the inhibition of glucose re-absorption in the proximal renal tubule (SGLT-2 inhibition).

Key words

Diabetes mellitus - re-absorption of glucose - proximale renal tubule - SGLT-2 inhibition

Literatur

• 1 IDF Diabetes Atlas.. Brussels: IDF; 2009
• 2 Kulzer B, Hermanns N, Gorges D et al.. Prevention of diabetes self-management program (PREDIAS): effects on weight, metabolic risk factors, and behavioral outcomes.  Diabetes Care. 2009;  32 1143-1146
• 3 Schindler C, Schellong S.. Drug-induced edema – pathophysiology, diagnosis and management.  Phlebologie. 2009;  38 33-41
• 4 Ehrenkranz JR, Lewis NG, Kahn CR et al.. Phlorizin: a review.  Diabetes Metab Res Rev. 2005;  21 31-38
• 5 Komoroski B, Vachharajani N, Boulton D et al.. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.  Clin Pharmacol Ther. 2009;  85 520-526
• 6 Komoroski B, Vachharajani N, Feng Y et al.. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.  Clin Pharmacol Ther. 2009;  85 513-519
• 7 List JF, Woo V, Morales E et al.. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.  Diabetes Care. 2009;  32 650-657
• 8 Wilding JP, Norwood P, T'Joen C et al.. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-indepen-dent treatment.  Diabetes Care. 2009;  32 1656-1662
• 9 Hussey EK, Clark RV, Amin DM et al.. Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus.  J Clin Pharmacol. EPub ahead of print 2010; 
• 10 Hussey EK, Dobbins RL, Stoltz RR et al.. Multiple-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double-Blind Study.  J Clin Pharmacol. EPub ahead of print 2010; 
• 11 Idris I, Donnelly R.. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.  Diabetes Obes Metab. 2009;  11 79-88
• 12 O'Malley D, Reimann F, Simpson AK et al.. Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing.  Diabetes. 2006;  55 3381-3386
• 13 Nair S, Wilding JP.. Sodium glucose cotranspor-ter 2 inhibitors as a new treatment for diabetes mellitus.  J Clin Endocrinol Metab. 2010;  95 34-42
• 14 Neumiller JJ, White Jr. J, Campbell RK.. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.  Drugs. 2010;  70 377-385
• 15 Trial watch: SGLT2 inhibitor shows promise in type 2 diabetes.  Nat Rev Drug Discov. 2010;  9 182

Korrespondenz